Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Juan Ramón Delgado Pérez"'
Autor:
Ruth Álvarez Cabellos, Francisco R García-Arroyo, Cristina Quero Blanco, Miguel Cruz, Antonio García Sánchez, Antonio Rueda, Josep Gumà-Padrò, José Gómez-Codina, Mariano Provencio, Marta Llanos, Juan Ramón Delgado Pérez, Luis de la Cruz
Publikováno v:
Leukemia & Lymphoma. :1-16
Autor:
Ruth Álvarez Cabellos, Luis de la Cruz, Miguel Á. Cruz Mora, Marta Llanos, Juan Ramón Delgado Pérez, Josep Gumá Padró, Antonio Sánchez, José Gómez-Codina, Mariano Provencio, Francisco R García-Arroyo, Cristina Quero Blanco, Antonio Rueda
Publikováno v:
Leukemialymphoma. 55(1)
Relapse is the main cause of therapeutic failure in follicular lymphoma (FL). We set out to evaluate the role of consolidation with Yttrium-90 ibritumomab tiuxetan in patients with intermediate- and high-risk FL after four cycles of CHOP-R (cyclophos
Autor:
J. García-García, Julia Ruiz-Vozmediano, Aranzazu González-Vicente, Juan Ramón Delgado Pérez, Verónica Conde-Herrero, Encarnación González-Flores, Cynthia González-Rivas, Beatriz González-Astorga, Lucia Castillo-Portellano, Isabel Linares
Publikováno v:
Annals of Oncology. 24:iv87
Autor:
Verónica Conde-Herrero, Rosario Del Moral Ávila, Joaquina Martínez-Galán, Beatriz González-Astorga, Jesús Soberino-García, Juan Ramón Delgado Pérez, Cynthia González-Rivas, Encarnación González-Flores, Julia Ruiz-Vozmediano, Lucia Castillo-Portellano
Publikováno v:
Annals of Oncology. 24:iv73
Autor:
Juan Ramón Delgado Pérez, Beatriz González-Astorga, Lucia Castillo-Portellano, Jesús Soberino-García, Encarnación González-Flores, Verónica Conde-Herrero, J. García-García, Julia Ruiz-Vozmediano, Cynthia González-Rivas
Publikováno v:
Annals of Oncology. 24:iv106
Autor:
Aranzazu González-Vicente, Encarnación González-Flores, Julia Ruiz-Vozmediano, Beatriz González-Astorga, Cynthia González-Rivas, Jose Antonio Ortega, Verónica Conde-Herrero, J. García-García, Juan Ramón Delgado Pérez, Jesús Soberino-García
Publikováno v:
Annals of Oncology. 24:iv106
Background: Absence of KRAS mutations is a predictive factor of response to anti-EGFR agents in the treatment of metastatic colorectal cancer (mCRC) but it does not seem to be associated with Bevacizumab (Bv) treatment’s outcomes. The aim of this s
Autor:
Juan Ramón Delgado Pérez, José Antonio Ortega-Dominguez, Verónica Conde-Herrero, Aranzazu González-Vicente, Julia Ruiz-Vozmediano, Lucia Castillo-Portellano, Encarnación González-Flores, Joaquina Martínez-Galán, Cynthia González-Rivas, Beatriz González-Astorga, Raquel Luque-Caro, Jesús Soberino-García, J. García-García
Publikováno v:
Annals of Oncology. 24:iv74
Primary tumor location was pancreas in 13 pts (25.5%), lung in 11 pts (21.6%), small or large intestine in 8 pts (15.7%), appendix in 5 pts (9.8%), and other locations in 14 pts (27.5%). Results: Thirty-two pts had low grade (Ki67 20%). 49% (25) of t
Autor:
Jesús Soberino-García, Lucia Castillo-Portellano, José Antonio Ortega-Dominguez, Juan Ramón Delgado Pérez, Joaquina Martínez-Galán, P. Ballesteros, Antonio Iriyogen, Cynthia González-Rivas, Julia Ruiz-Vozmediano
Publikováno v:
Annals of Oncology. 24:iv74
A Retrospective Analysis of Adjuvant Chemotherapy in Elderly Patients. Experience of Our Institution
Autor:
Lucia Castillo-Portellano, Cynthia González-Rivas, Jesús Soberino-García, Aranzazu González-Vicente, Beatriz González-Astorga, Joaquina Martínez-Galán, J. García-García, Encarnación González-Flores, Verónica Conde-Herrero, Juan Ramón Delgado Pérez, José Antonio Ortega-Dominguez, Julia Ruiz-Vozmediano
Publikováno v:
Annals of Oncology. 24:iv102
Autor:
Beatriz González-Astorga, Encarnación González-Flores, Juan Ramón Delgado Pérez, J. García-García, Julia Ruiz-Vozmediano, Raquel Luque-Caro, Cynthia González-Rivas, Verónica Conde-Herrero, Lucia Castillo-Portellano, Jesús Soberino-García
Publikováno v:
Annals of Oncology. 24:iv109
Background: Bevacizumab has efficacy in first-line treatment of advanced colorectal cancer. The overall response with Bevacizumab is low in some studies. Not know the ideal method of assessing response to therapy with bevacizumab. Metabolic imaging o